Perioperative Pembro Approved to Up Chance of HNSCC Cure

The FDA has approved a before and after surgery regimen for pembrolizumab to improve outcomes in resectable locally-advanced head and neck squamous cell carcinoma (HNSCC). Specifically, the new approval is for HNSCC tumors that express PD-L1, with pembrolizumab as a single agent in the neoadjuvant setting…